[HTML][HTML] Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic …
H Yanai, H Adachi, M Hakoshima, H Katsuyama - Metabolites, 2023 - mdpi.com
Beyond lowering plasma glucose levels, sodium–glucose cotransporter 2 inhibitors
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney …
H Yanai, H Adachi, M Hakoshima… - Metabolites (2218 …, 2023 - search.ebscohost.com
Beyond lowering plasma glucose levels, sodium–glucose cotransporter 2 inhibitors
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
Significance of Endothelial Dysfunction Amelioration for Sodium-Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney …
H Yanai, H Adachi, M Hakoshima, H Katsuyama - Metabolites, 2023 - europepmc.org
Beyond lowering plasma glucose levels, sodium–glucose cotransporter 2 inhibitors
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney …
H Yanai, H Adachi, M Hakoshima, H Katsuyama - Metabolites, 2023 - search.proquest.com
Beyond lowering plasma glucose levels, sodium–glucose cotransporter 2 inhibitors
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
Significance of Endothelial Dysfunction Amelioration for Sodium-Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney …
H Yanai, H Adachi, M Hakoshima… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Beyond lowering plasma glucose levels, sodium-glucose cotransporter 2 inhibitors
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
[HTML][HTML] Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic …
H Yanai, H Adachi, M Hakoshima, H Katsuyama - Metabolites, 2023 - ncbi.nlm.nih.gov
Beyond lowering plasma glucose levels, sodium–glucose cotransporter 2 inhibitors
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …
(SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the …